CD8A and neoplasm: Furthermore, the systemic delivery of NPsiCTLA‐4 increased the trafficking rate of both CD4+ and CD8+ T‐lymphocytes, with a decreased extension ratio for CD4+ FOXP3+ regulatory T cells, resulting in tumor growth inhibition.